Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug.
about
Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis)Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approachesAnkylosing spondylitis: A state of the art factual backboneCurrent evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitisTherapeutic potential of COX-2 inhibitors in arthritis.New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy.Efficacy and safety of celecoxib in chinese patients with ankylosing spondylitis: a 6-week randomized, double-blinded study with 6-week open-label extension treatmentNovel therapies in the treatment of spondyloarthritis.Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study.Ankylosing spondylitis: introductory comments on its diagnosis and treatment.Treatment trials in ankylosing spondylitis: current and future considerations.Conventional treatments for ankylosing spondylitis.Recent progress in ankylosing spondylitis treatment.Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway.Assessment of enthesitis in ankylosing spondylitis.Ankylosing spondylitis. Not just another pain in the backHigh-dose thalidomide increases the risk of peripheral neuropathy in the treatment of ankylosing spondylitisExpanding the armamentarium for the spondyloarthropathies.Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care.Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials.Ankylosing spondylitis: recent breakthroughs in diagnosis and treatmentNetwork Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury.Management and evaluation of extra-articular manifestations in spondyloarthritisDevelopments and current pharmacotherapeutic recommendations for ankylosing spondylitis.Clinical pharmacology of celecoxib, a COX-2 selective inhibitor.Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists.Current therapeutics for spondyloarthritis.First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath AnkylosMonitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes.Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials.Infusion of umbilical cord mesenchymal stem cells alleviates symptoms of ankylosing spondylitis.Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses.Therapies of Early, Advanced, and Late Onset Forms of Axial Spondyloarthritis, and the Need for Treat to Target Strategies.Anti-TNF agents for the treatment of spondyloarthropathies.Blinding images to sequence in osteoarthritis: evidence from other diseases.A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor alpha inhibitorsInfluence of hydrophilic polymers on celecoxib complexation with hydroxypropyl beta-cyclodextrin.Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients.
P2860
Q24186403-3532C701-EB44-4925-8F3E-9DB7207A1115Q24536027-269A0529-0247-4228-BC77-8DAE2CAC3DE0Q24806367-4F5A811C-DE5B-4A71-8C95-0BB37FE5BBBEQ26782184-BF7ED8AC-7DB0-428E-A64E-410F7FD6C027Q33222422-AE75DA97-9C53-44C5-BFFA-FB9653706142Q34481579-E6EE3347-3292-4728-B479-A41C26FE9616Q34560574-1CACCC6B-2F5F-4B76-A52D-A520289BDDBBQ34705364-57DB8601-D3F8-4BCD-BC1D-C82045574E8BQ34706981-F2C386B6-7DD8-4BC5-AA0D-79C895897E84Q34808170-3E5825D6-F47A-4A5D-9290-99E66C705E6CQ34967487-76F0D05F-4468-4CA4-B79C-47DF65774D0AQ34967507-394404B3-C032-4E3E-92CF-9ED7200CE89DQ34967537-06ECAD4C-FA83-4560-81AE-F44755FB3E33Q35040745-88EC4504-0F30-47F7-B151-FF89F65A3C6DQ35098611-3F3D018F-9BFC-41F0-8019-52F319D30C3CQ35552370-56A1E966-7778-4FD4-A319-208DBD1507E9Q35682200-AC74BCF8-3E04-433E-8A10-12DA7FB14A9DQ35746349-8436622D-E870-440B-A2A5-CDBB96E040F1Q35823657-EF9205D3-F436-4DA3-8D2C-A49C762B1CDCQ35940404-C3ED55DF-ED73-4C2E-A8E8-CD89B1C2A552Q36013803-634AE44F-22A8-4460-ACC3-BD67DF06F0DEQ36143588-49342901-76CC-488B-BAEB-8223B78744BFQ36195392-F518413F-FF0A-49E8-BAF2-C27335C39F2DQ36439889-D47053CD-EEE0-4790-82F1-751C0E29FE2AQ36458447-83CBA1B4-4A3C-4E67-9015-C6E55CE80FB9Q36904910-4038BAE5-33E3-4084-AFD1-32F6CB971EFCQ37085249-AE38B76B-D471-487C-834D-B72D6E2673BAQ37944297-65B2BA68-F063-46AE-B3EB-640F4814B1D7Q38003531-64965207-CB74-453A-9E42-A54FDF687FF6Q38010372-0F1FCFF1-E1B3-4D10-94A5-81A413E2DD08Q38517691-69372B76-62F1-4042-9498-D812F7B4A7D6Q38561891-78AAEF5E-D71A-4285-BCF5-8F5706C996F0Q38646267-290A889F-3EB7-47ED-B3C7-83E2A7485B46Q38993297-41F20A95-1B4B-4A07-833F-23B8F1342CCFQ39135959-09FE5B22-5D4D-475A-97F3-6672108CCDE3Q40409369-F32851E8-468D-4D10-AD1A-099B8AB0D4E7Q40691535-41F75C69-15E1-4578-A95D-7011AB71C438Q41876223-B20A0329-41E9-430C-A539-0CFBE7E7C377Q42016692-A841657A-1A5F-403A-BC5F-574B718A2741Q42340219-87833A03-A77B-4EF6-B543-5F0A0AB87C0D
P2860
Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Efficacy of celecoxib, a cyclo ...... eroidal antiinflammatory drug.
@ast
Efficacy of celecoxib, a cyclo ...... eroidal antiinflammatory drug.
@en
type
label
Efficacy of celecoxib, a cyclo ...... eroidal antiinflammatory drug.
@ast
Efficacy of celecoxib, a cyclo ...... eroidal antiinflammatory drug.
@en
prefLabel
Efficacy of celecoxib, a cyclo ...... eroidal antiinflammatory drug.
@ast
Efficacy of celecoxib, a cyclo ...... eroidal antiinflammatory drug.
@en
P2093
P2860
P1476
Efficacy of celecoxib, a cyclo ...... eroidal antiinflammatory drug.
@en
P2093
Dougados M
Jolchine I
Olivieri I
van der Heijde D
P2860
P304
P356
10.1002/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K
P577
2001-01-01T00:00:00Z